Ophthalmic drugs companies focus on the development of medications and therapies for eye-related conditions and diseases. These companies provide a wide range of ophthalmic drugs, including those for glaucoma, macular degeneration, and inflammatory eye disorders. Ophthalmic drugs companies contribute to vision care and eye health by delivering innovative and effective treatments for various ocular conditions.
Regeneron Pharmaceuticals Received FDA approval for their Vabysmo (faricimab) for the treatment of wet age-related macular degeneration (wet AMD), offering an alternative to existing anti-VEGF drugs. Partnering with research institutions on developing gene therapies for inherited retinal diseases.
Novartis Completed the sale of five ophthalmic medications, including Lucentis (ranibizumab) and Xalatan (latanoprost), as part of their strategic reshuffle. Continuing research on their pipeline of ophthalmic drugs, including novel treatments for presbyopia and dry eye disease.
Roche Launched their Vitenka (ganciclovir implant) for the treatment of cytomegalovirus retinitis (CMV retinitis) in HIV/AIDS patients, offering a sustained-release alternative to traditional injections. Investing in research on gene therapies and stem cell therapies for retinal diseases.
Alimera Sciences Received FDA approval for their Iluvien (fluocinolone acetonide implant) for the treatment of diabetic macular edema (DME), providing long-term steroid release with a single implant. Focusing on developing minimally invasive drug delivery systems for various eye diseases.
Santen Pharmaceutical Co., Ltd Received FDA approval for their KIOVIGON (cetuximab-hyaluronic acid) for the treatment of corneal epithelial erosion, representing a novel drug-biopolymer combination in ophthalmology. Actively involved in developing innovative therapies for glaucoma, dry eye disease, and other ocular conditions.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)